Shionogi & Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Isao Teshirogi
- Full Time Employees
- 6,223
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1-8, Doshomachi 3-chome Osaka OS Japan 541-0045
- IPO Date
- Feb 28, 2018
- CIK
- 0001281721
- Website
- shionogi.com
- Similar Companies
- Business
- Shionogi & Co., Ltd. Shionogi & Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals, diagnostic reagents, and medical devices. The company offers a diverse portfolio of prescription drugs targeting infectious diseases including gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, and complicated urinary tract infections; antiviral agents such as baloxavir marboxil; antibacterials like cefiderocol; treatments for chronic pain, neuropathic pain, hyperlipidemia, cancer of the esophagus, bladder, head and neck, and solid tumors; as well as products for allergies including Claritin, cardiovascular diseases, insomnia, acne, dyspareunia, ADHD, Alzheimer's disease, and chronic liver disease with brands such as Naldemedine, lusutrombopag, Osphena, Cymbalta, and adapalene. Shionogi operates primarily in Japan, North America, Europe, and other regions worldwide through more than 20 subsidiaries and maintains sales and supply networks across multiple countries. Founded in 1878 and headquartered in Osaka, Japan, the company focuses on high unmet medical needs in anti-infectives, pain management, and rare diseases. In recent developments, Shionogi completes the acquisition of Japan Tobacco Inc.'s pharmaceutical subsidiaries Torii Pharmaceutical Co., Ltd. and Akros Pharma Inc. for approximately $1.1 billion in 2025, bolstering its global R&D capabilities particularly in AI drug discovery and integrating around 700 employees; it also acquires TORII PHARMACEUTICAL CO., LTD. as a wholly-owned subsidiary in September 2025 and merges with U.S. biotech Qpex Biopharma to extend its infectious disease innovation platform.
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript
Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript
Shionogi: Likely The Last Viable COVID Play